REFERENCES

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Guidelines for Diagnosing and Managing Disseminated Histoplasmosis among People Living with HIV [Internet]. Washington (DC): Pan American Health Organization; 2020 Apr.

Cover of Guidelines for Diagnosing and Managing Disseminated Histoplasmosis among People Living with HIV

Guidelines for Diagnosing and Managing Disseminated Histoplasmosis among People Living with HIV [Internet].

Show details

Contents

< PrevNext >

REFERENCES

1.: Joint United Nations Programme on HIV/AIDS (UNAIDS). Data 2019. Geneva: UNAIDS; 2019. Available from: https://www.unaids.org/en/resources/documents/2019/2019-UNAIDS-data. Accessed 12 March 2020.
2.: Pan American Health Organization. Tuberculosis in the Americas, 2018. Washington. D.C.: PAHO; 2018. Available from: http://iris.paho.org/xmlui/handle/123456789/49510. Accessed 12 March 2020).
3.: World Health Organization. Guidelines for managing advanced HIV disease and rapid initiation of antiretroviral therapy. Geneva: WHO; 2017. Available from https://www.who.int/hiv/pub/guidelines/advanced-HIV-disease/en. Accessed 12 March 2020. [PubMed: 29341560]
4.: Adenis AA, Valdes A, Cropet C, McCotter OZ, Derado G, Couppie P, et al. Burden of HIV-associated histoplasmosis compared with tuberculosis in Latin America: a modelling study. Lancet Infect Dis 2018;18:1150–9. [PMC free article: PMC6746313] [PubMed: 30146320]
5.: Calderon EJ, de Armas Y, Panizo MM, Wissmann G. Pneumocystis jirovecii pneumonia in Latin America. A public health problem? Expert Rev Anti Infect Ther 2013;11:565–70. [PubMed: 23750728]
6.: Rajasingham R, Smith RM, Park BJ, Jarvis JN, Govender NP, Chiller TM, et al. Global burden of disease of HIV-associated cryptococcal meningitis: an updated analysis. Lancet Infect Dis 2017;17:873–81. [PMC free article: PMC5818156] [PubMed: 28483415]
7.: Neglected Histoplasmosis in Latin America Group. Disseminated histoplasmosis in Central and South America, the invisible elephant: the lethal blind spot of international health organizations. AIDS 2016;30:167–70. [PubMed: 26684816]
8.: Bahr NC, Antinori S, Wheat LJ, Sarosi GA. Histoplasmosis infections worldwide: thinking outside of the Ohio River valley. Curr Trop Med Rep 2015;2:70–80. [PMC free article: PMC4535725] [PubMed: 26279969]
9.: Adenis A, Nacher M, Hanf M, Basurko C, Dufour J, Huber F, et al. Tuberculosis and histoplasmosis among human immunodeficiency virus-infected patients: a comparative study. Am J Trop Med Hyg 2014;90:216–23. [PMC free article: PMC3919221] [PubMed: 24394475]
10.: Hage CA, Azar MM, Bahr N, Loyd J, Wheat LJ. Histoplasmosis: up-to-date evidence-based approach to diagnosis and management. Semin Respir Crit Care Med 2015;36:729–45. [PubMed: 26398539]
11.: Pasqualotto AC, Quieroz-Telles F. Histoplasmosis dethrones tuberculosis in Latin America. Lancet Infect Dis 2018;18:1058–60. [PubMed: 30146319]
12.: Caceres DH, Valdes A. Histoplasmosis and tuberculosis co-occurrence in people with advanced HIV. J Fungi (Basel) 2019;5. [PMC free article: PMC6787747] [PubMed: 31404979]
13.: World Health Organization. Guidelines for the diagnosis, prevention and management of cryptococcal disease in HIV-infected adults, adolescents and children. Supplement to the 2016 consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Geneva: WHO; 2018. Available from https://www.who.int/hiv/pub/guidelines/cryptococcal-disease/en. Accessed 12 March 2020). [PubMed: 30285342]
14.: World Health Organization. Second WHO model list of essential in vitro diagnostics. Geneva: WHO; 2019. Available from: https://www.who.int/medical_devices/publications/Standalone_document_v8.pdf?ua=1. Accessed 12 March 2020.
15.: World Health Organization. WHO model list of essential medicines. Geneva: WHO; 2019. Available from: https://apps.who.int/iris/bitstream/handle/10665/325771/WHO-MVP-EMP-IAU-2019.06-eng.pdf?ua=1. Accessed 12 March 2020.
16.: Azar MM, Hage CA. Clinical perspectives in the diagnosis and management of histoplasmosis. Clin Chest Med 2017;38(3):403–15. [PubMed: 28797485]
17.: Samayoa B, Roy M, Cleveland AA, Medina N, Lau-Bonilla D, Scheel CM, et al. High mortality and coinfection in a prospective cohort of human immunodeficiency virus/acquired immune deficiency syndrome patients with histoplasmosis in Guatemala. Am J Trop Med Hyg 2017;97:42–8. [PMC free article: PMC5508883] [PubMed: 28719316]
18.: Caceres DH, Zuluaga A, Arango-Bustamante K, de Bedout C, Tobon AM, Restrepo A, et al. Implementation of a training course increased the diagnosis of histoplasmosis in Colombia. Am J Trop Med Hyg 2015;93:662–7. [PMC free article: PMC4559714] [PubMed: 26123961]
19.: Caceres DH, Knuth M, Derado G, Lindsley MD. Diagnosis of progressive disseminated histoplasmosis in advanced HIV: a meta-analysis of assay analytical performance. J Fungi (Basel) 2019;5. [PMC free article: PMC6787751] [PubMed: 31426618]
20.: De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008;46:1813–21. [PMC free article: PMC2671227] [PubMed: 18462102]
21.: Bansal N, Sethuraman N, Gopalakrishnan R, Ramasubramanian V, Kumar DS, Nambi PS, et al. Can urinary histoplasma antigen test improve the diagnosis of histoplasmosis in a tuberculosis endemic region? Mycoses 2019;62:505–7. [PubMed: 30734964]
22.: Falci DR, Monteiro AA, Braz Caurio CF, Magalhaes TCO, Xavier MO, Basso RP, et al. Histoplasmosis, an underdiagnosed disease affecting people living with HIV/AIDS in Brazil: results of a multicenter prospective cohort study using both classical mycology tests and histoplasma urine antigen detection. Open Forum Infect Dis 2019;6:ofz073. [PMC free article: PMC6461557] [PubMed: 30997365]
23.: Wheat LJ, Connolly-Stringfield PA, Baker RL, Curfman MF, Eads ME, Israel KS, et al. Disseminated histoplasmosis in the acquired immune deficiency syndrome: clinical findings, diagnosis and treatment, and review of the literature. Medicine (Baltimore) 1990;69:361–74. [PubMed: 2233233]
24.: Johnson PC, Wheat LJ, Cloud GA, Goldman M, Lancaster D, Bamberger DM, et al. Safety and efficacy of liposomal amphotericin B compared with conventional amphotericin B for induction therapy of histoplasmosis in patients with AIDS. Ann Intern Med. 2002;137:105–9. [PubMed: 12118965]
25.: Wheat LJ, Freifeld AG, Kleiman MB, Baddley JW, McKinsey DS, Loyd JE, et al. Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the Infectious Diseases Society of America. Clin Infect Dis 2007;45:807–25. [PubMed: 17806045]
26.: Murphy RA, Gounder L, Manzini TC, Ramdial PK, Castilla C, Moosa MY. Challenges in the management of disseminated progressive histoplasmosis in human immunodeficiency virus–infected patients in resource-limited settings. Open Forum Infect Dis 2015;2:ofv025. [PMC free article: PMC4438904] [PubMed: 26034774]
27.: Damasceno LS, Ramos AN Jr, Alencar CH, Goncalves MV, de Mesquita JR, Soares AT, et al. Disseminated histoplasmosis in HIV-infected patients: determinants of relapse and mortality in a north-eastern area of Brazil. Mycoses 2014;57:406–13. [PubMed: 24612078]
28.: Myint T, Anderson AM, Sanchez A, Farabi A, Hage C, Baddley JW, et al. Histoplasmosis in patients with human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS): multicenter study of outcomes and factors associated with relapse. Medicine (Baltimore) 2014;93:11–8. [PMC free article: PMC4616326] [PubMed: 24378739]
29.: Murray M, Hine P. Treating progressive disseminated histoplasmosis in people living with HIV. Cochrane Database Syst Rev. 2020;(4):CD013594. 10.1002/14651858.CD013594 [PMC free article: PMC7192368] [PubMed: 32343003] [CrossRef]
30.: Wheat J, MaWhinney S, Hafner R, McKinsey D, Chen D, Korzun A, et al. Treatment of histoplasmosis with fluconazole in patients with acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Acquired Immunodeficiency Syndrome Clinical Trials Group and Mycoses Study Group. Am J Med 1997;103:223–32. [PubMed: 9316555]
31.: Wheat J, Hafner R, Korzun AH, Limjoco MT, Spencer P, Larsen RA, et al. Itraconazole treatment of disseminated histoplasmosis in patients with the acquired immunodeficiency syndrome. AIDS Clinical Trial Group. Am J Med 1995;98:336–42. [PubMed: 7709945]
32.: Drew RH. Pharmacotherapy of disseminated histoplasmosis in patients with AIDS. Ann Pharmacother 1993;27:1510–8. [PubMed: 8305787]
33.: Norris S, Wheat J, McKinsey D, Lancaster D, Katz B, Black J, et al. Prevention of relapse of histoplasmosis with fluconazole in patients with the acquired immunodeficiency syndrome. Am J Med 1994;96:504–8. [PubMed: 8017447]
34.: Sharkey-Mathis PK, Velez J, Fetchick R, Graybill JR. Histoplasmosis in the acquired immunodeficiency syndrome (AIDS): treatment with itraconazole and fluconazole. J Acquir Immune Defic Syndr 1993;6:809–19. [PubMed: 8389850]
35.: Hecht FM, Wheat J, Korzun AH, Hafner R, Skahan KJ, Larsen R, et al. Itraconazole maintenance treatment for histoplasmosis in AIDS: a prospective, multicenter trial. J Acquir Immune Defic Syndr Hum Retrovirol 1997;16:100–7. [PubMed: 9358104]
36.: World Health Organization. Update of recommendations on first- and second-line antiretroviral regimens. Geneva: WHO; 2019. Available from https://www.who.int/hiv/pub/arv/arv-update-2019-policy/en. Accessed 12 March 2020.
37.: Negroni R, Messina F, Arechavala A, Santiso G, Bianchi M. [Efficacy of the treatment and secondary antifungal prophylaxis in AIDS-related histoplasmosis. Experience at the Francisco J. Muniz Infectious Diseases Hospital in Buenos Aires]. Rev Iberoam Micol 2017;34:94–8. [PubMed: 28391953]
38.: Melzani A, De Reynal De Saint Michel R, Ntab B, Djossou F, Epelboin L, Nacher M, et al. Incidence and trends in immune reconstitution inflammatory syndrome associated with Histoplasma capsulatum among people living with HIV: a 20-year case series and literature review. Clin Infect Dis 2020;70:643–52. [PubMed: 30921453]
39.: Zolopa A, Andersen J, Powderly W, Sanchez A, Sanne I, Suckow C, et al. Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial. PLoS One 2009;4:e5575. [PMC free article: PMC2680972] [PubMed: 19440326]
40.: Drayton J, Dickinson G, Rinaldi MG. Coadministration of rifampin and itraconazole leads to undetectable levels of serum itraconazole. Clin Infect Dis 1994;18:266. [PubMed: 8161649]
41.: Agudelo CA, Restrepo CA, Molina DA, Tobon AM, Kauffman CA, Murillo C, et al. Tuberculosis and histoplasmosis co-infection in AIDS patients. Am J Trop Med Hyg 2012;87:1094–8. [PMC free article: PMC3516081] [PubMed: 23128292]
42.: Andes D, Pascual A, Marchetti O. Antifungal therapeutic drug monitoring: established and emerging indications. Antimicrob Agents Chemother 2009;53:24–34. [PMC free article: PMC2612175] [PubMed: 18955533]
43.: Bellmann R, Smuszkiewicz P. Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients. Infection 2017;45:737–79. [PMC free article: PMC5696449] [PubMed: 28702763]
44.: Bahr NC, Rolfes MA, Musubire A, Nabeta H, Williams DA, Rhein J, et al. Standardized electrolyte supplementation and fluid management improves survival during amphotericin therapy for cryptococcal meningitis in resource-limited settings. Open Forum Infect Dis 2014;1:ofu070. [PMC free article: PMC4281785] [PubMed: 25734140]
45.: Dismukes WE, Bradsher RW Jr, Cloud GC, Kauffman CA, Chapman SW, George RB, et al. Itraconazole therapy for blastomycosis and histoplasmosis. NIAID Mycoses Study Group. Am J Med 1992;93:489–97. [PubMed: 1332471]
46.: Lestner JM, Roberts SA, Moore CB, Howard SJ, Denning DW, Hope WW. Toxicodynamics of itraconazole: implications for therapeutic drug monitoring. Clin Infect Dis 2009;49:928–30. [PubMed: 19681707]
47.: Caceres DH, Tobón Á M, Restrepo Á, Chiller T, Gómez BL. The important role of co-infections in patients with AIDS and progressive disseminated histoplasmosis (PDH): a cohort from Colombia. Med Mycol Case Rep 2018;19:41–4. [PMC free article: PMC5775073] [PubMed: 29379705]
48.: Caceres DH, Scheel CM, Tobon AM, Ahlquist Cleveland A, Restrepo A, Brandt ME, et al. Validation of an enzyme-linked immunosorbent assay that detects Histoplasma capsulatum antigenuria in Colombian patients with AIDS for diagnosis and follow-up during therapy. Clin Vaccine Immunol 2014;21:1364–8. [PMC free article: PMC4178582] [PubMed: 25008902]
49.: Caceres DH, Gomez BL, Tobon AM, Chiller TM, Lindsley MD. Evaluation of a Histoplasma antigen lateral flow assay for the rapid diagnosis of progressive disseminated histoplasmosis in Colombian patients with AIDS. Mycoses 2020;63:139–44. [PubMed: 31625627]
50.: World Health Organization. Guidelines for declaration of interests (WHO experts). Geneva: WHO; 2017. Available from: http://www.who.int/medicines/news/2017/Guidelines_for_Declaration_of_Interests_WHO_Experts_51b2CRD.pdf. Accessed 12 March 2020.
51.: World Health Organization. Handbook for guideline development. Geneva: WHO; 2018. Available from: https://www.who.int/publications/guidelines/handbook_2nd_ed.pdf?ua=1. Accessed 12 March 2020.
52.: Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol 2009;62:1006–12. [PubMed: 19631508]
53.: Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336:924–6. [PMC free article: PMC2335261] [PubMed: 18436948]
54.: Caceres DH, Adenis A, de Souza JVB, Gomez BL, Cruz KS, Pasqualotto AC et al. The Manaus Declaration: current situation of histoplasmosis in the Americas, Report of the II Regional Meeting of the International Histoplasmosis Advocacy Group. Curr Fungal Infect Rep 2019;13:244–9.

Sales, rights, and licensing. To purchase PAHO publications, visit http://publications.paho.org. To submit requests for commercial use and queries on rights and licensing, visit http://www.paho.org/permissions.

Third-party materials. If material that is attributed to a third party, such as tables, figures, or images, is reused from this work, it is the user’s responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned material or component from this work rests solely with the user.

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO license (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo).

Under the terms of this license, this work may be copied, redistributed, and adapted for non-commercial purposes, provided the new work is issued using the same or equivalent Creative Commons license and it is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that the Pan American Health Organization (PAHO) and the World Health Organization (WHO) endorses any specific organization, product, or service. Use of the PAHO and WHO logo is not permitted.

Bookshelf ID: NBK587191

Contents

< PrevNext >

PubReader
Print View
Cite this Page
Guidelines for Diagnosing and Managing Disseminated Histoplasmosis among People Living with HIV [Internet]. Washington (DC): Pan American Health Organization; 2020 Apr. REFERENCES.
PDF version of this title (1.3M)